What is the step‑by‑step workup for a patient with elevated AST and ALT (transaminitis)?

Workup for Transaminitis

For a patient with elevated AST and ALT, begin by repeating the liver panel within 2–4 weeks if elevations are mild (<5× ULN), within 2–5 days if moderate (5–10× ULN), or within 2–3 days if severe (>10× ULN or ALT ≥3× ULN with bilirubin ≥2× ULN), then proceed with a systematic evaluation based on the enzyme pattern and clinical context. 1

Step 1: Confirm and Characterize the Elevation

Repeat Testing Based on Severity

• Mild elevation (<5× ULN, approximately <200–250 IU/L): Repeat comprehensive liver panel (ALT, AST, alkaline phosphatase, total and direct bilirubin, albumin, INR) in 2–4 weeks to establish trend and exclude transient causes 1, 2
• Moderate elevation (5–10× ULN): Repeat within 2–5 days because this level is uncommon in benign conditions like NAFLD and warrants closer observation 1
• Severe elevation (>10× ULN or ALT ≥3× ULN with bilirubin ≥2× ULN): Repeat within 2–3 days with immediate comprehensive evaluation including direct bilirubin, INR, and creatine kinase 1

Determine the Pattern of Injury

• Hepatocellular pattern: ALT and AST disproportionately elevated compared to alkaline phosphatase (R-value ≥5, where R = [ALT÷ULN ALT] / [ALP÷ULN ALP]) 3, 4
• Cholestatic pattern: Alkaline phosphatase disproportionately elevated (R-value ≤2) 3
• Mixed pattern: R-value between 2 and 5 3

Check AST:ALT Ratio

• AST:ALT ratio <1: Suggests NAFLD, viral hepatitis, or medication-induced injury 1, 2
• AST:ALT ratio ≥2: Highly suggestive of alcoholic liver disease (>98% specificity when ratio >1.5) 2
• AST:ALT ratio ≥1 in nonalcoholic disease: Strongly suspect cirrhosis 2

Step 2: Obtain Detailed Clinical History

Alcohol Consumption

• Quantify current and past intake using validated instruments like AUDIT-C 3
• Define thresholds: ≥14–21 drinks/week in men or ≥7–14 drinks/week in women suggests alcoholic liver disease 2
• Even moderate consumption (≥30 g/day in men, ≥20 g/day in women) can cause enzyme elevations 2

Medication Review

• Review all prescription drugs, over-the-counter products, herbal supplements, and dietary supplements 1, 2
• Check medications against the LiverTox® database for hepatotoxic potential 2
• Medication-induced liver injury causes 8–11% of cases with mildly elevated enzymes 2

Metabolic Risk Factors

• Assess for obesity (BMI, waist circumference ≥94 cm men/≥80 cm women), type 2 diabetes, hypertension, and dyslipidemia—all components of metabolic syndrome that increase NAFLD risk 1, 2
• NAFLD affects up to 30% of the population and is the most common cause of unexplained transaminase elevation 1, 5

Viral Hepatitis Risk Factors

• Country of birth, injection drug use, high-risk sexual behavior, occupational exposures 3
• HIV status, as coinfection affects liver enzyme levels and management 1, 6

Family History

• Liver disease, autoimmune conditions, early cirrhosis without alcohol abuse (suggests hereditary conditions) 3, 7

Step 3: Perform Targeted Physical Examination

• Calculate BMI 3
• Examine abdomen for hepatosplenomegaly and ascites 3
• Look for stigmata of chronic liver disease: spider angiomata, palmar erythema, jaundice 3
• Assess for symptoms: fatigue, jaundice, pruritus, right upper quadrant pain 1

Step 4: Order Core Laboratory Panel

Essential Initial Tests

• Complete blood count with platelets (needed for FIB-4 calculation and to assess for thrombocytopenia suggesting portal hypertension) 1, 3
• Comprehensive metabolic panel including creatinine 3
• Complete liver panel: Total and direct bilirubin, albumin, INR (to assess synthetic function) 1, 2, 4
• Viral hepatitis serologies: HBsAg, anti-HBc (IgM if acute suspected), anti-HCV 1, 2, 3
• Iron studies: Serum iron, total iron-binding capacity, ferritin (transferrin saturation >45% suggests hemochromatosis) 1, 2, 5
• Fasting glucose or HbA1c and fasting lipid panel (to assess metabolic syndrome) 1, 2
• Creatine kinase (CK) to exclude muscle injury as source of AST elevation 1, 2
• Thyroid function tests to rule out thyroid disorders 1, 2

Additional Tests Based on Pattern

• If cholestatic pattern: Check GGT to confirm hepatic origin of alkaline phosphatase elevation 3
• If marked elevation (>1000 U/L): Consider hepatitis A and E testing 3

Step 5: Obtain Abdominal Ultrasound

• First-line imaging with 84.8% sensitivity and 93.6% specificity for moderate-to-severe hepatic steatosis 1, 2
• Identifies fatty liver, biliary obstruction, structural abnormalities, focal lesions, and signs of portal hypertension 1, 2, 3
• Perform early to establish baseline and identify conditions requiring urgent intervention 2

Step 6: Calculate FIB-4 Score for Fibrosis Risk

FIB-4 = (Age × AST) / (Platelet count × √ALT)

Interpretation:

• Low risk (<1.3, or <2.0 if age >65): ≥90% negative predictive value for advanced fibrosis 1, 2
• Indeterminate risk (1.3–2.67): Consider additional testing or monitoring 2
• High risk (>2.67): Indicates advanced fibrosis; requires hepatology referral 1, 2

Step 7: Order Additional Testing Based on Initial Results

If Initial Tests Are Normal or Suggest NAFLD

• Implement lifestyle modifications: 7–10% weight loss, low-carbohydrate/low-fructose diet, 150–300 minutes/week moderate-intensity aerobic exercise 1, 2
• Manage metabolic comorbidities: statins for dyslipidemia, GLP-1 agonists or SGLT2 inhibitors for diabetes 1, 2

If Suspecting Autoimmune Hepatitis

• Autoimmune markers: ANA, anti-smooth muscle antibody, quantitative IgG levels 1, 2, 5
• Anti-mitochondrial antibody if cholestatic pattern (for primary biliary cholangitis) 3, 5

If Suspecting Hemochromatosis

• Genetic testing if ferritin elevated and transferrin saturation >45% 1, 5

If Suspecting Less Common Causes

• α₁-antitrypsin level (for α₁-antitrypsin deficiency) 1, 5
• Ceruloplasmin level (for Wilson disease, especially if age <40) 1, 5
• Celiac disease screening if clinically indicated 2, 5

Step 8: Establish Monitoring Plan

For Mild Elevations (<2× ULN)

• Repeat liver enzymes in 2–4 weeks 1, 2
• If stable or improving, continue monitoring every 4–8 weeks until normalized 2
• If increasing to ≥3× ULN, repeat within 2–5 days and intensify evaluation 1

For Moderate Elevations (2–5× ULN)

• Monitor weekly for 2 weeks, then biweekly until normalized 1
• If ALT >3× baseline or >300 U/L, repeat within 2–3 days 1

For Identified NAFLD

• Monitor ALT every 3 months during first year, then every 6–12 months if stable 1

Step 9: Determine Need for Referral

Urgent Hepatology Referral Indicated When:

• ALT >8× ULN or >5× baseline in those with elevated baseline 3
• ALT ≥3× ULN with total bilirubin ≥2× ULN (Hy's Law—suggests drug-induced liver injury with risk of acute liver failure) 1, 3
• Evidence of synthetic dysfunction: Elevated INR, low albumin, thrombocytopenia 1, 2
• FIB-4 score >2.67 (high risk for advanced fibrosis) 1, 2
• Imaging suggests cirrhosis or focal lesions 3

Non-Urgent Referral Indicated When:

• Transaminases remain elevated ≥6 months without identified cause 1, 2, 5
• Persistent elevation >2× ULN after 3 months despite addressing modifiable factors 3
• Diagnosis remains unclear after non-invasive evaluation 1

Common Pitfalls to Avoid

• Don't simply repeat the same tests without a diagnostic plan—84% of abnormal liver enzymes remain abnormal at 1 month, so persistent elevation requires systematic evaluation 1, 3
• Don't assume mild elevations are benign—normal ALT does not exclude significant liver disease; up to 50% of NAFLD patients and 10% with advanced fibrosis have normal ALT 1, 2
• Don't miss viral hepatitis—HBV and HCV may be asymptomatic but require treatment 3
• Don't forget to check creatine kinase—AST can be elevated from muscle injury; CK differentiates hepatic from muscular origin 1, 2
• Don't overlook medication-induced injury—review all drugs, supplements, and herbals against LiverTox® database 2
• Don't delay repeat testing in symptomatic patients—new hepatic symptoms (jaundice, fever, malaise, vomiting, pruritus) warrant repeat testing within 2–3 days regardless of enzyme levels 1
• Don't ignore the AST:ALT ratio—ratio ≥2 is highly specific for alcoholic liver disease and ratio ≥1 in nonalcoholic disease suggests cirrhosis 2